We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Test Detects Early Mouth Cancer

By LabMedica International staff writers
Posted on 24 Oct 2012
A gene test that can detect precancerous cells in patients with benign-looking mouth lesions could potentially allow at-risk patients to receive earlier treatment, significantly improving their chance of survival. More...


The test is less invasive than the standard histopathology methods as it requires only a 1-2 mm piece of tissue and it takes less than three hours to get the results, compared to up to a week for standard histopathology where biopsy tissue taken during an operation is examined under a microscope by a pathologist.

Scientists at Queen Mary, University of London (UK) showed that the quantitative Malignancy Index Diagnostic System (qMIDS) test had a cancer detection rate of 91% to 94% when used on more than 350 head and neck tissue specimens from 299 patients in the UK and Norway. The qMIDS test measures the levels of 16 genes, which are converted, via a diagnostic algorithm, into a "malignancy index" which quantifies the risk of the lesion becoming cancerous.

The test is based on a cancer gene encoding the Forkhead box protein (FOXM1) - (isoform B). The FOXM1 gene is highly expressed in many cancer types. The 14 associated genes are implicated in the regulation of the cell cycle, differentiation, aging, genomic stability, epigenetic and stem cell renewal. Two reference genes are included in the test.

Diagnostic test performance was assessed using detection rate (DR) and false-positive rate (FPR).The median qMIDS scores were 1.3, in healthy tissue, 2.9 in dysplasia, and 6.7 in head and neck squamous cell carcinomas (HNSCC).. At a qMIDS cut-off of 4.0, DR was 94% and FPR was 3.2% for a Norwegian dataset; and DR was 91% and FPR was 1.3% for the UK dataset. In this study, the investigators further demonstrated the transferability of qMIDS for diagnosing 58 premalignant human vulva and 21 skin squamous cell carcinomas, illustrating its potential clinical use for other cancer types.

Mouth cancer affects more than 6,200 people in the UK each year and more than half a million people worldwide, with global figures estimated to rise above one million a year by 2030. Muy-Teck Teh, PhD, the lead investigator and inventor of the test, said, “A sensitive test capable of quantifying a patient's cancer risk is needed to avoid the adoption of a 'wait-and-see' intervention. Detecting cancer early, coupled with appropriate treatment can significantly improve patient outcomes, reduce mortality and alleviate long-term public healthcare costs.” The study was published on October 4, 2012, in the journal International Journal of Cancer.

Related Links:

Queen Mary, University of London



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automated Clinical Chemistry Analyzer
Envoy 500+
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.